JUN and neoplasm: There was little significant reduction in tumour weight in the TamR tumour-bearing group that underwent tamoxifen treatment, but SP600125 treatment diminished tumour growth and inhibited the phosphorylation of c-Jun in vivo (Fig. 6f–h).